PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer.

Abstract The favorable prognosis of women with non-small-cell lung cancer (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We investigated whether this observation could be explained by the expression of estrogen receptor-alpha (ER-α) in tumor tissue.
PMID
Related Publications

Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.

Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.

Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.

Authors

Mayor MeshTerms
Keywords

Prognostic factor

estrogen receptor

first-line chemotherapy

gender difference

immunohistochemistry

palliative chemotherapy

sex hormones

Journal Title anticancer research
Publication Year Start


 


PMID- 29599348
OWN - NLM
STAT- MEDLINE
DCOM- 20180412
LR  - 20180412
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 4
DP  - 2018 Apr
TI  - Expression of Estrogen Receptor-alpha and Survival in Advanced-stage Non-small
      Cell Lung Cancer.
PG  - 2261-2269
AB  - BACKGROUND/AIM: The favorable prognosis of women with non-small-cell lung cancer 
      (NSCLC) compared to men might be explained by sex hormone-related mechanisms. We 
      investigated whether this observation could be explained by the expression of
      estrogen receptor-alpha (ER-alpha) in tumor tissue. MATERIALS AND METHODS:
      Archived, formalin fixed, paraffin embedded tumor tissue samples were
      retrospectively analyzed for nuclear expression of ER-alpha with
      immunohistochemistry. RESULTS: Biopsies from 222 patients were analyzed.
      Twenty-three percent were ER-alpha positive. Fifty-four percent of the patients
      were men and 46% of the tumors were adenocarcinomas. One hundred-nine (49%)
      patients received pemetrexed and carboplatin and 113 (51%) received gemcitabine
      and carboplatin. Females with ER-alpha positive tumors who received PC had a
      substantial survival benefit over all other groups (20 vs. 4.6 months; p=0.003). 
      CONCLUSION: ER-alpha is an independent prognostic factor in advanced NSCLC and
      might also be a predictive factor for response to pemetrexed/carboplatin in
      women.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Lund-Iversen, Marius
AU  - Lund-Iversen M
AD  - Department of Pathology, Oslo University Hospital, Oslo, Norway
      [email protected]
AD  - Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
FAU - Scott, Helge
AU  - Scott H
AD  - Department of Pathology, Oslo University Hospital, Oslo, Norway.
AD  - Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
FAU - Strom, Erik H
AU  - Strom EH
AD  - Department of Pathology, Oslo University Hospital, Oslo, Norway.
FAU - Theiss, Noah
AU  - Theiss N
AD  - Ventana Medical Systems, Tucson, AZ, U.S.A.
FAU - Brustugun, Odd Terje
AU  - Brustugun OT
AD  - Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen,
      Norway.
FAU - Gronberg, Bjorn H
AU  - Gronberg BH
AD  - Department of Clinical and Molecular Medicine, NTNU, Norwegian University of
      Science and Technology, Trondheim, Norway.
AD  - The Cancer Clinic, St. Olav's Hospital, Trondheim University Hospital, Trondheim,
      Norway.
LA  - eng
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Estrogen Receptor alpha)
RN  - 0 (estrogen receptor alpha, human)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 0W860991D6 (Deoxycytidine)
RN  - B76N6SBZ8R (gemcitabine)
RN  - BG3F62OND5 (Carboplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/*metabolism/mortality/pathology
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Disease Progression
MH  - Estrogen Receptor alpha/*metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Lung Neoplasms/drug therapy/*metabolism/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Pemetrexed/administration & dosage
MH  - Retrospective Studies
OTO - NOTNLM
OT  - *Prognostic factor
OT  - *estrogen receptor
OT  - *first-line chemotherapy
OT  - *gender difference
OT  - *immunohistochemistry
OT  - *palliative chemotherapy
OT  - *sex hormones
EDAT- 2018/03/31 06:00
MHDA- 2018/04/13 06:00
CRDT- 2018/03/31 06:00
PHST- 2018/02/13 00:00 [received]
PHST- 2018/03/02 00:00 [revised]
PHST- 2018/03/05 00:00 [accepted]
PHST- 2018/03/31 06:00 [entrez]
PHST- 2018/03/31 06:00 [pubmed]
PHST- 2018/04/13 06:00 [medline]
AID - 38/4/2261 [pii]
AID - 10.21873/anticanres.12470 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Apr;38(4):2261-2269. doi: 10.21873/anticanres.12470.